News articles about ProNAi Therapeutics (NASDAQ:SRRA) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ProNAi Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 47.1794357476935 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- Analysts Issue Forecasts for ProNAi Therapeutics, Inc.’s FY2017 Earnings (SRRA) (americanbankingnews.com)
- ProNAi Therapeutics, Inc. to Post FY2017 Earnings of ($0.84) Per Share, SunTrust Banks Forecasts (SRRA) (americanbankingnews.com)
- Financial Review: ProNAi Therapeutics (SRRA) & DURECT Corporation (DRRX) (americanbankingnews.com)
- ProNAi Therapeutics, Inc. (SRRA) Issues Earnings Results, Beats Expectations By $0.03 EPS (americanbankingnews.com)
- Sierra Oncology Reports Third Quarter Results (finance.yahoo.com)
SRRA has been the subject of a number of recent research reports. ValuEngine upgraded shares of ProNAi Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Jefferies Group LLC reiterated a “hold” rating on shares of ProNAi Therapeutics in a report on Thursday, July 27th. Finally, Zacks Investment Research downgraded shares of ProNAi Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 26th. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $4.00.
Shares of ProNAi Therapeutics (NASDAQ SRRA) opened at $1.93 on Tuesday. ProNAi Therapeutics has a 1-year low of $1.10 and a 1-year high of $2.25.
ProNAi Therapeutics (NASDAQ:SRRA) last posted its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.03. sell-side analysts forecast that ProNAi Therapeutics will post -0.86 earnings per share for the current fiscal year.
About ProNAi Therapeutics
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.